PT  - JOURNAL ARTICLE
AU  - Liu, Jing
AU  - Li, Sumeng
AU  - Liu, Jia
AU  - Liang, Boyun
AU  - Wang, Xiaobei
AU  - Wang, Hua
AU  - Li, Wei
AU  - Tong, Qiaoxia
AU  - Yi, Jianhua
AU  - Zhao, Lei
AU  - Xiong, Lijuan
AU  - Guo, Chunxia
AU  - Tian, Jin
AU  - Luo, Jinzhuo
AU  - Yao, Jinghong
AU  - Pang, Ran
AU  - Shen, Hui
AU  - Peng, Cheng
AU  - Liu, Ting
AU  - Zhang, Qian
AU  - Wu, Jun
AU  - Xu, Ling
AU  - Lu, Sihong
AU  - Wang, Baoju
AU  - Weng, Zhihong
AU  - Han, Chunrong
AU  - Zhu, Huabing
AU  - Zhou, Ruxia
AU  - Zhou, Helong
AU  - Chen, Xiliu
AU  - Ye, Pian
AU  - Zhu, Bin
AU  - He, Shengsong
AU  - He, Yongwen
AU  - Jie, Shenghua
AU  - Wei, Ping
AU  - Zhang, Jianao
AU  - Lu, Yinping
AU  - Wang, Weixian
AU  - Zhang, Li
AU  - Li, Ling
AU  - Zhou, Fengqin
AU  - Wang, Jun
AU  - Dittmer, Ulf
AU  - Lu, Mengji
AU  - Hu, Yu
AU  - Yang, Dongliang
AU  - Zheng, Xin
TI  - Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
AID  - 10.1101/2020.02.16.20023671
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.16.20023671
4099  - http://medrxiv.org/content/early/2020/02/22/2020.02.16.20023671.short
4100  - http://medrxiv.org/content/early/2020/02/22/2020.02.16.20023671.full
AB  - Background The dynamic changes of lymphocyte subsets and cytokines profiles of patients with novel coronavirus disease (COVID-19) and their correlation with the disease severity remain unclear.Methods Peripheral blood samples were longitudinally collected from 40 confirmed COVID-19 patients and examined for lymphocyte subsets by flow cytometry and cytokine profiles by specific immunoassays.Results Of the 40 COVID-19 patients enrolled, 13 severe cases showed significant and sustained decreases in lymphocyte counts but increases in neutrophil counts than 27 mild cases. Further analysis demonstrated significant decreases in the counts of T cells, especially CD8 + T cells, as well as increases in IL-6, IL-10, IL-2 and IFN-γ levels in the peripheral blood in the severe cases compared to those in the mild cases. T cell counts and cytokine levels in severe COVID-19 patients who survived the disease gradually recovered at later time points to levels that were comparable to those of the mild cases. Moreover, the neutrophil-to-CD8+ T cell ratio (N8R) were identified as the most powerful prognostic factor affecting the prognosis for severe COVID-19.Conclusions The degree of lymphopenia and a proinflammatory cytokine storm is higher in severe COVID-19 patients than in mild cases, and is associated with the disease severity. N8R may serve as a useful prognostic factor for early identification of severe COVID-19 cases.Summary Lymphocyte subsets and cytokine profiles in the peripheral blood of COVID-19 patients were longitudinally characterized. The study revealed the kinetics features of immune parameters associated with the disease severity and identified N8R as a useful prognostic factor for predicting severe COVID-19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Natural Science Foundation of China (81861138044, 91742114 and 91642118), the National Science and Technology Major Project (2018ZX10723203, 2018ZX10302206, 2017ZX10202201, 2017ZX10202202 and 2017ZX10202203), the Innovation Team Project of Health Commission of Hubei Province (WJ2019C003), the Integrated Innovative Team for Major Human Diseases Program of Tongji Medical College and the “Double-First Class” Project for the International Cooperation Center on Infection and Immunity, HUST, and a special joint project of University Hospital Essen, University of Duisburg-Essen.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.